Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHOP-G01: Sequential HIPEC with Oxaliplatin and Paclitaxel for Gastric Cancer
NCT01471132Phase 2Unknown
- Sponsor
- Peking University
- Start
- Sep 2011
- Primary completion
- Sep 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and paclitaxel in gastric cancer (GC), sponsored by Peking University. Primary endpoint: Overall Survival at 24 months. Status: unknown.
02
Drugs
oxaliplatinpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01471132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01471132.